NCT05578625招募中不适用
Circulating Tumor DNA Methylation Sequencing for Multiple Myeloma Minimal Residual Disease Detection and Clonal Evolution Monitoring
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2022年8月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Sample Collection Completed
研究概览
简要总结
- To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods for MM;
- Carry out ctDNA-based methylation sequencing in newly diagnosed, remission, and, relapsed MM patients, to track the clonal evolution patterns; and explore the in the initial diagnosis-remission-relapse stage of MM, track the clonal evolution characteristics of methylation profiles in MM patients during the disease progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For myeloma patients: i) Age no less than 18 and no more than 75; ii) Diagnosed with symptomatic multiple myeloma according to IMWG consensus; iii) Provide informed consent in accordance with the declaration of Helsinki.
- •For healthy controls: i) Age no less than 18 and no more than 75; ii) Provide informed consent in accordance with the declaration of Helsinki.
排除标准
- •For myeloma patients: i) Insufficient amount of peripheral blood obtained; ii) Methylation sequencing failed due to technical reasons.
- •For healthy controls: i) Insufficient amount of peripheral blood obtained; ii) Methylation sequencing failed due to technical reasons.
结局指标
主要结局
Sample Collection Completed
时间窗: From Aug 31 2022 to Jun 30 2025
When the peripheral blood samples required for the study have been collected
次要结局
未报告次要终点
研究者
Gang An
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
Institute of Hematology & Blood Diseases Hospital, China
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRDMultiple MyelomaNCT05530096Sir Mortimer B. Davis - Jewish General Hospital70
招募中
不适用
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)CarcinomaKidney NeoplasmsKidney CancerRenal Cell CarcinomaRCCNCT05917106Jinling Hospital, China450
已完成
不适用
Liquid Biopsy Using Methylation Sequencing for Lung CancerDiagnoses DiseaseLung CancerNCT04253509Samsung Medical Center280
进行中（未招募）
不适用
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma PatientsMultiple MyelomaNCT04108624University of Chicago56
已完成
不适用
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCTMDSMRDSCTNCT02872662Nordic MDS Group308